• Radnostix closed the acquisition of key assets from Lucerno Dynamics, adding the LARA System platform, ELLEXA Explorer software, and related intellectual property.
• The technology targets radiopharmaceutical administration, aiming to reduce IV extravasations through monitoring features, including real-time visualization.
• Radnostix plans to develop the assets into new nuclear medicine device offerings, including dosimetry and uptake monitoring tools.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radnostix Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.